All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health, GSK, and Novartis, and supported through independent educational grants from Blueprint Medicines, Incyte, Bristol Myers Squibb and Merck Sharp & Dohme LLC, Rahway, NJ, USA. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
EHA2026 | Top abstracts in MPN
| Oral presentations: Friday, June 12 | |||
| Abstract | Title | Presenter | Time (CEST) |
| S210 | Development of a G6B directed antibody drug conjugate for the treatment of myeloproliferative neoplasms | Adam Mead | 17:15–17:30 |
| S213 | CD9 marks the disease-propagating hematopoietic stem cell population in myelofibrosis | Lara Tavernari | 17:45–18:00 |
| S214 | Transcriptional subtypes of myelofibrosis are independent of driver mutations and capture distinct biology, outcomes, and disease trajectories | Andy Zeng | 18:00–18:15 |
| Oral presentations: Saturday, June 13 | |||
| Abstract | Title | Presenter | Time (CEST) |
| S215 | Efficacy and safety of luspatercept in patients with myelofibrosis on Janus kinase inhibitors who require red blood cell transfusions: Primary analysis of the phase 3 INDEPENDENCE trial | Francesco Passamonti | 17:15–17:30 |
| S216 | Mutant calreticulin–specific monoclonal antibody, INCA033989, is well tolerated and achieves robust spleen, anemia, and molecular responses in patients (pts) with myelofibrosis (MF) | Claire Harrison | 17:30–17:45 |
| S217 | Efficacy and safety of bezuclastinib in patients with advanced systemic mastocytosis: Primary results from the APEX study | Daniel J. DeAngelo | 17:45–18:00 |
| S218 | Results of AJX-101, a phase 1 clinical trial of the type II JAK2 inhibitor AJ1-11095, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor | John Mascarenhas | 18:00–18:15 |
| S219 | Early versus delayed initiation of ropeginterferon alfa-2b in high-risk essential thrombocythaemia: Two-year results from the phase 3 SURPASS-ET study | Harinder Gill | 18:15–18:30 |
| Oral presentations: Sunday, June 14 | |||
| Abstract | Title | Presenter | Time (CEST) |
| LB5002 | Selinexor plus ruxolitinib in Janus kinase inhibitor–naïve myelofibrosis: Phase 3 sentry trial | Claire Harrison | 09:30–09:45 |
| Posters | |||
| Abstract | Title | Presenter | Date and time (CEST) |
| PF886 | Divesiran, a novel GalNAc conjugated siRNA, reduces phlebotomies, improves iron stores and symptoms in polycythemia vera patients in SANRECO phase 1 study | Marina Kremyanskaya | Friday, June 12, from 18:45 |
| PF890 | Thromboembolic and progression events in phlebotomy-dependent patients with polycythemia vera (PV): Long-term results from the phase 2 REVIVE and THRIVE open-label extension rusfertide studies | Naveen Pemmaraju | Friday, June 12, from 18:45 |
| PF891 | Effect of rusfertide on cytoreductive therapy use in patients with phlebotomy dependent polycythemia vera: Post hoc analysis from the randomized controlled phase 3 VERIFY study | Francesca Palandri | Friday, June 12, from 18:45 |
| PF894 | Evaluation of pelabresib (PELA) as add-on therapy to Janus kinase inhibitor (JAKi) ruxolitinib (RUX) in myelofibrosis (MF) patients: Results from Arm 2 of the open-label, phase 2 MANIFEST study | Marina Kremyanskaya | Friday, June 12, from 18:45 |
| PF909 | RESTORE-PV – A phase 2 open-label study evaluating the safety and efficacy of the anti-TMPRSS6 monoclonal antibody DISC-3405 in participants with polycythemia vera | Naseema Gangat | Friday, June 12, from 18:45 |
| PF912 | Hematologic control and improved safety following crossover from anagrelide to ropeginterferon alfa-2b in patients with essential thrombocythemia: Data from the SURPASS-ET study | Lucia Masarova | Friday, June 12, from 18:45 |
| PS1983 | Mutant calreticulin–specific monoclonal antibody, INCA033989, is well tolerated and achieves rapid and sustained hematologic and molecular responses in patients with essential thrombocythemia (ET) | John Mascarenhas | Saturday, June 13, from 18:45 |
| PS1984 | Fedratinib + nivolumab combination improves outcomes in myelofibrosis patients resistant or suboptimally responding to JAK-inhibitor therapy – Results from the FRACTION trial (IKF051) | Susanne Isfort | Saturday, June 13, from 18:45 |
| PS1985 | Investigational PIM1 inhibitor nuvisertib in combination with momelotinib showed promising clinical activity in patients with myelofibrosis and anemia: Data from an ongoing global phase 1/2 study | James McCloskey | Saturday, June 13, from 18:45 |
| PS1986 | Ropeginterferon alfa-2b demonstrates molecular and hematologic responses with a favorable safety profile in essential thrombocythemia | Harinder Gill | Saturday, June 13, from 18:45 |
| PS1987 | Pelabresib monotherapy in myelofibrosis after Janus kinase inhibitor failure: Results from Arm 1 of the open-label, phase 2 MANIFEST study | Moshe Talpaz | Saturday, June 13, from 18:45 |
| PS1995 | Outcomes with momelotinib in patients with intermediate-1– vs intermediate-2–/high-risk myelofibrosis: Post hoc analyses of the phase 3 SIMPLIFY-1 and MOMENTUM trials | Prithviraj Bose | Saturday, June 13, from 18:45 |
| PS1997 | Update from the phase 2 RESTORE trial of elritercept in patients with myelofibrosis (MF) receiving ruxolitinib | Ciro Rinaldi | Saturday, June 13, from 18:45 |
| PS2002 | Dynamic cytopenia patterns in myelofibrosis: A real-world analysis from the ERNEST-3 registry | Tiziano Barbui | Saturday, June 13, from 18:45 |
| PS2005 | SHORESPAN-017: A phase 3 extension study evaluating the safety of continued bomedemstat in participants with essential thrombocythemia | Francesca Palandri | Saturday, June 13, from 18:45 |
| PS2010 | Consistency of response by baseline platelet count in pacritinib-treated patients in the real world: MY-PAC analysis | James Rossetti | Saturday, June 13, from 18:45 |
| PS2013 | Analysis of variant allele frequency of JAK2V617F in patients with polycythemia vera treated with either ruxolitinib or best available therapy in the randomized phase 2b RUXOBEAT clinical trial | Madeline Caduc | Saturday, June 13, from 18:45
|
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
